183 related articles for article (PubMed ID: 28791425)
21. Rab27A regulates transport of cell surface receptors modulating multinucleation and lysosome-related organelles in osteoclasts.
Shimada-Sugawara M; Sakai E; Okamoto K; Fukuda M; Izumi T; Yoshida N; Tsukuba T
Sci Rep; 2015 Apr; 5():9620. PubMed ID: 25882854
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
[TBL] [Abstract][Full Text] [Related]
23. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
24. 9-Hydroxy-6,7-dimethoxydalbergiquinol inhibits osteoclast differentiation through down-regulation of Akt, c-Fos and NFATc1.
Kim JY; Kim JY; Cheon YH; Kwak SC; Baek JM; Kim YC; Yoon KH; Oh J; Lee MS
Int Immunopharmacol; 2014 May; 20(1):213-20. PubMed ID: 24630975
[TBL] [Abstract][Full Text] [Related]
25. Parthenolide inhibits osteoclast differentiation and bone resorbing activity by down-regulation of NFATc1 induction and c-Fos stability, during RANKL-mediated osteoclastogenesis.
Kim JY; Cheon YH; Yoon KH; Lee MS; Oh J
BMB Rep; 2014 Aug; 47(8):451-6. PubMed ID: 24314143
[TBL] [Abstract][Full Text] [Related]
26. Chlorogenic acid inhibits osteoclast differentiation and bone resorption by down-regulation of receptor activator of nuclear factor kappa-B ligand-induced nuclear factor of activated T cells c1 expression.
Kwak SC; Lee C; Kim JY; Oh HM; So HS; Lee MS; Rho MC; Oh J
Biol Pharm Bull; 2013; 36(11):1779-86. PubMed ID: 23985829
[TBL] [Abstract][Full Text] [Related]
27. RNA-binding protein Musashi2 induced by RANKL is critical for osteoclast survival.
Fujiwara T; Zhou J; Ye S; Zhao H
Cell Death Dis; 2016 Jul; 7(7):e2300. PubMed ID: 27441652
[TBL] [Abstract][Full Text] [Related]
28. Desoxyrhapontigenin inhibits RANKL‑induced osteoclast formation and prevents inflammation‑mediated bone loss.
Tran PT; Park DH; Kim O; Kwon SH; Min BS; Lee JH
Int J Mol Med; 2018 Jul; 42(1):569-578. PubMed ID: 29693149
[TBL] [Abstract][Full Text] [Related]
29. Rab44 Deficiency Induces Impaired Immune Responses to Nickel Allergy.
Noguromi M; Yamaguchi Y; Sato K; Oyakawa S; Okamoto K; Murata H; Tsukuba T; Kadowaki T
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674510
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-124 regulates osteoclast differentiation.
Lee Y; Kim HJ; Park CK; Kim YG; Lee HJ; Kim JY; Kim HH
Bone; 2013 Oct; 56(2):383-9. PubMed ID: 23867221
[TBL] [Abstract][Full Text] [Related]
31. Docosahexaenoic acid signaling attenuates the proliferation and differentiation of bone marrow-derived osteoclast precursors and promotes apoptosis in mature osteoclasts.
Kim HJ; Ohk B; Yoon HJ; Kang WY; Seong SJ; Kim SY; Yoon YR
Cell Signal; 2017 Jan; 29():226-232. PubMed ID: 27836739
[TBL] [Abstract][Full Text] [Related]
32. Phospholipase C-related, but catalytically inactive protein (PRIP) up-regulates osteoclast differentiation via calcium-calcineurin-NFATc1 signaling.
Murakami A; Matsuda M; Harada Y; Hirata M
J Biol Chem; 2017 May; 292(19):7994-8006. PubMed ID: 28341745
[TBL] [Abstract][Full Text] [Related]
33. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells.
Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR
BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757
[TBL] [Abstract][Full Text] [Related]
34. Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB.
Kim WS; Kim HJ; Lee ZH; Lee Y; Kim HH
Exp Cell Res; 2013 Feb; 319(4):436-46. PubMed ID: 23246654
[TBL] [Abstract][Full Text] [Related]
35. FOXO1 mediates RANKL-induced osteoclast formation and activity.
Wang Y; Dong G; Jeon HH; Elazizi M; La LB; Hameedaldeen A; Xiao E; Tian C; Alsadun S; Choi Y; Graves DT
J Immunol; 2015 Mar; 194(6):2878-87. PubMed ID: 25694609
[TBL] [Abstract][Full Text] [Related]
36. Large Rab GTPases: Novel Membrane Trafficking Regulators with a Calcium Sensor and Functional Domains.
Tsukuba T; Yamaguchi Y; Kadowaki T
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299309
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
[TBL] [Abstract][Full Text] [Related]
38. Identification of LRRc17 as a negative regulator of receptor activator of NF-kappaB ligand (RANKL)-induced osteoclast differentiation.
Kim T; Kim K; Lee SH; So HS; Lee J; Kim N; Choi Y
J Biol Chem; 2009 May; 284(22):15308-16. PubMed ID: 19336404
[TBL] [Abstract][Full Text] [Related]
39. Transcriptional Modulator Ifrd1 Regulates Osteoclast Differentiation through Enhancing the NF-κB/NFATc1 Pathway.
Iezaki T; Fukasawa K; Park G; Horie T; Kanayama T; Ozaki K; Onishi Y; Takahata Y; Nakamura Y; Takarada T; Yoneda Y; Nakamura T; Vacher J; Hinoi E
Mol Cell Biol; 2016 Oct; 36(19):2451-63. PubMed ID: 27381458
[TBL] [Abstract][Full Text] [Related]
40. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.
He L; Lee J; Jang JH; Lee SH; Nan MH; Oh BC; Lee SG; Kim HH; Soung NK; Ahn JS; Kim BY
Bone; 2012 Jun; 50(6):1207-13. PubMed ID: 22484180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
